Evidence map›Paper›PMID 29595562›Full record

Trial reportCritical care medicine2018

Effect of Administration of Ramelteon, a Melatonin Receptor Agonist, on the Duration of Stay in the ICU: A Single-Center Randomized Placebo-Controlled Trial.

Mitsuaki Nishikimi, Atsushi Numaguchi, Kunihiko Takahashi, Yasuhiro Miyagawa, Kota Matsui, Michiko Higashi, Go Makishi, Shigeyuki Matsui, Naoyuki Matsuda

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Critical care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 11 pooled it
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 11 syntheses or guidelines pooled it, 132 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Effects of Ramelteon on the Prevention of Postoperative Delirium in Older Patients Undergoing Orthopedic Surgery: The RECOVER Randomized Controlled Trial.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2021
    Trial
  17. Trial
  18. Trial
  19. A pilot, parallel-group, blinded, placebo-controlled, randomiseCritical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine · 2026
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Mitsuaki NishikimiDepartment of Emergency and Critical Care, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Atsushi NumaguchiDepartment of Emergency and Critical Care, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kunihiko TakahashiDepartment of Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Yasuhiro MiyagawaDepartment of Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kota MatsuiDepartment of Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Michiko HigashiDepartment of Emergency and Critical Care, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Go MakishiDepartment of Emergency and Critical Care, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shigeyuki MatsuiDepartment of Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Naoyuki MatsudaDepartment of Emergency and Critical Care, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nagoya University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesOccurrence of delirium in the ICU is associated with a longer stay in the ICU. To examine whether the use of ramelteon, a melatonin agonist, can prevent delirium and shorten the duration of ICU stay of critically ill patients.

designA single-center, triple-blinded, randomized placebo-controlled trial.

settingICU of an academic hospital. PATIENTS: Eligible patients were ICU patients who could take medicines orally or through a nasogastric tube during the first 48 hours of admission.

interventionsThe intervention group received ramelteon (8 mg/d), and the control group received placebo (1 g/d of lactose powder) at 20:00 hours every day until discharge from the ICU. MEASUREMENTS AND MAIN

resultsA total of 88 subjects were randomized to the ramelteon group (45 subjects) or the placebo group (43 subjects). As the primary endpoint, there was a trend toward decrease in the duration of ICU stay (4.56 d) in the ramelteon group compared with the placebo group (5.86 d) (p = 0.082 and p = 0.028 before and after adjustments). As the secondary endpoints, statistically significant decreases in the occurrence rate (24.4% vs 46.5%; p = 0.044) and duration (0.78 vs 1.40 d; p = 0.048) of delirium were observed in the ramelteon group. The nonintubated patients of the ramelteon group showed statistically significantly fewer awakenings per night and a higher proportion of nights without awakenings.

conclusionsRamelteon tended to decrease the duration of ICU stay as well as decreased the occurrence rate and duration of delirium statistically significantly.

Indexed as

AgedDeliriumDouble-Blind MethodFemaleHumansIndenesIntensive Care UnitsLength of StayMaleMiddle AgedReceptors, MelatoninIndenesramelteonReceptors, Melatonin

Identifiers

PMID29595562
PMCPMC6012040
OpenAlexW2912384565

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.